Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non–muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical TrialAnirban P. Mitra, Colin P. Dinney, Sharada Mokkapati et al.|European Urology|2021Cited by 24